Eli Lilly and Company has entered a strategic collaboration with Hong Kong-listed Metis TechBio to develop tissue-specific drug delivery technologies. The partners will work on lipid nanoparticle methods to target treatments to specific tissues, using Metis’s AI-driven platform.
The deal could be worth up to $1.1 billion to Metis TechBio, including an upfront payment and milestone payments tied to research and development achievements.
The collaboration reflects a wider trend of major pharmaceutical companies partnering with biotech firms that specialize in AI-powered drug discovery and delivery systems to improve therapeutic efficacy.